VentriPoint Diagnostics Ltd. announce the appointment of a new Interim CEO and President, Hugh MacNaught, who has been serving on the Ventripoint Board of Directors since 2020 and is a proven leader in biotech commercialization. As the Company enters its next phase of customer adoption and commercialization of Ventripoints groundbreaking AI technology, Mr. MacNaught brings 30 years of experience in developing and commercializing medical technologies. He will be dealing directly with the Company's partners, as well as potential and current customers, who are now using Ventripoints A.I.-powered technology to turn ultrasound images into MRI-quality images of the heart.

The Company wishes to thank Dr. Alvira Macanovic, who has served as Ventripoints CEO and President over the last 13 months and has been instrumental in advancing the technology and current partnerships. Ventripoint is now poised to focus on driving clinical awareness and adoption of AI technology by the worlds healthcare providers, said Mr. MacNaught, Interim CEO and President. look forward to bringing this innovation in A.I. health care to hospitals and patients around the world.

Ventripoints patented A.I.-powered technology turns ultrasound scans of the heart into MRI-quality images. The technology allows A.I. heart scans to be taken in minutes, at a fraction of the cost of an MRI, alleviating waiting lines and capital costs in the health care system. Aside from being an inexpensive alternative, Ventripoint technology is also ideal for use with infants and children who often cant be given an MRI because of the need for sedation or contrast media as well as the requirement to remain motionless.

Also, VMS+ may be a suitable alternative for adult patients with pacemakers since many of these devices are not MRI-compatible. Iwant to thank the entire Ventripoint team, who have spent many years helping bring A.I. technology to major hospitals and heart-care teams in Canada, Europe and the United States, said Ventripoint Board Chair Dr. George Adams. As Hugh moves into the Interim CEO and President role and continues building new partnerships and sales, the Board will start a search for a permanent CEO and President. Added MacNaught: Im excited about the months ahead.

expect to launch next version of Ventripoints A.I. heart-imaging technology in the spring, following FDA clearance. This next version is even simpler to use and integrates easily into the diagnostic workflow of hospitals and clinics. MacNaught is a seasoned entrepreneur with over 30 years of experience founding, building, and managing medical product companies.

His career includes roles within multinational corporations including Nordion Healthcare Solutions LLC (Atomic Energy of Canada Limited), Eastman Kodak Company, Boehringer Mannheim GmbH (Roche), and Philips Corporate Technologies, and the venture capital industry. A serial entrepreneur, he has founded, financed and led several ventures and is a mentor in the entrepreneurship programs at Simon Fraser University and the University of British Columbia. He brings direct experience with diagnostics and medical AI technologies and looks forward to leveraging his broad commercial experience and leadership in the medical technology sector to drive growth for the Company.